Search Results

Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN004, an antibody drug conjugate (ADC) targeting the 5T4 oncofetal antigen (trophoblast glycoprotein), that is expressed in a wide range of malignant tumors but shows very limited expression in normal tissues.

Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the second half of 2026.

Align Technology, Inc. a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, announced an agreement with Asana, Inc., a leading work management platform for teams.

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

Genflow Biosciences Strengthens Pre-Clinical Efforts with FDA Guidance and CDMO and CRO Selection

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), wishes to announce that